Outset Medical (NASDAQ:OM) Releases Earnings Results, Misses Expectations By $0.04 EPS

Outset Medical (NASDAQ:OM) posted its earnings results on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04), Zacks reports. Outset Medical had a negative return on equity of 164.92% and a negative net margin of 122.84%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Stock Up 3.5 %

Outset Medical stock traded up $0.03 during trading hours on Wednesday, hitting $0.94. 1,529,358 shares of the stock traded hands, compared to its average volume of 1,386,158. Outset Medical has a one year low of $0.44 and a one year high of $5.22. The firm’s 50-day moving average price is $0.96 and its two-hundred day moving average price is $0.85. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12. The company has a market cap of $50.48 million, a PE ratio of -0.34 and a beta of 2.01.

Analyst Ratings Changes

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research report on Tuesday, January 7th.

Insider Transactions at Outset Medical

In related news, General Counsel John L. Brottem sold 32,930 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total transaction of $26,344.00. Following the completion of the transaction, the general counsel now owns 181,188 shares of the company’s stock, valued at $144,950.40. This trade represents a 15.38 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Leslie Trigg sold 65,236 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total value of $52,188.80. Following the transaction, the chief executive officer now owns 895,580 shares of the company’s stock, valued at $716,464. The trade was a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 267,790 shares of company stock valued at $222,243. Corporate insiders own 4.10% of the company’s stock.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.